Saturday 17 October 2026
Export ACB’s income statement to Excel — free account
Aurora Cannabis Inc.
ACB Healthcare Drug Manufacturers Specialty & Generic
Aurora Cannabis Inc.’s revenue for fiscal 2026 (year ended March 2026) was $232.0 million, down 5.95% from fiscal 2025. In the quarter to June 2026, revenue fell 31.2%, EPS grew 75.0%, free cash flow fell 293.6% and total debt fell 82.5%, each against the same quarter a year earlier.
3.99
0.11
−2.68%
Follow ACB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.82 | 0.80 | 0.90 | 1.28 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(53.59) | (733.60) | 19.22 | (11.49) | |
P/B ratio |
0.45 | 0.50 | 0.59 | 0.82 | |
Price to Tangible BV |
0.51 | 0.56 | 0.66 | 0.92 | |
EV/Sales |
0.58 | 0.53 | 0.74 | 1.15 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.95) | (12.65) | (28.81) | 185.39 | |
EV/FCF |
(3.35) | (4.89) | (9.25) | (25.01) | |
Quick Ratio |
2.59 | 3.13 | 1.36 | 1.52 | |
Current Ratio |
5.36 | 5.94 | 3.06 | 3.41 | |
Net Debt/EBITDA |
34.68 | 13.80 | (9.14) | 4.15 | |
Debt/Assets |
2.71% | 3.02% | 12.25% | 12.52% | |
Debt/Equity |
0.03 | 0.04 | 0.17 | 0.17 | |
Asset Turnover |
0.40 | 0.44 | 0.46 | 0.46 | |
Operating CF/Net income |
1.10 | 0.01 | 9.54 | 0.78 | |
Capex/Depreciation |
(1.10) | 8.65 | (1.22) | (0.78) | |
Interest Coverage |
(18.82) | 2.33 | 1.04 | (8.37) | |
Research and Development Expense of Revenue |
3.75% | 2.57% | 1.38% | 1.00% | |
Selling, General and Administrative Expense of Revenue |
60.52% | 107.67% | 42.54% | 51.75% | |
Intangible Assets out of Total Assets |
0.10 | 0.10 | 0.08 | 0.08 | |
Share Based Compensation of Revenue |
1.03% | (5.37%) | 2.35% | 5.51% | |
Graham Net Nets |
1.26 | 1.20 | 0.71 | 0.51 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(50.54%) | (47.71%) | (25.59%) | (11.58%) | |
Free Cash Flow Yield |
(20.98%) | (13.64%) | (8.89%) | (3.59%) | |
Revenue per Share |
0.79 | 0.49 | 1.19 | 1.16 | |
Operating CF per Share |
(0.05) | 0.00 | 0.22 | (0.52) | |
Capex per Share |
(0.06) | (0.07) | (0.07) | (0.07) | |
Free Cash Flow per Share |
(0.12) | (0.08) | 0.15 | (0.59) | |
Cash per Share |
1.75 | 2.10 | 1.95 | 1.83 | |
Shareholders Equity per Share |
6.17 | 6.53 | 7.18 | 7.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.17 | 6.53 | 7.18 | 7.29 | |
Free Cash Flow |
(7.12) | (4.28) | 8.67 | (33.37) | |
Working Capital |
231.15 | 239.23 | 215.12 | 217.57 | |
Capital Expenditures |
(3.91) | (4.03) | (3.78) | (4.08) | |
Net Current Asset Value |
216.48 | 223.07 | 170.98 | 169.92 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.08 | 0.14 | 0.06 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
28.99 | 31.39 | 33.53 | 31.68 | |
Average Payables |
49.91 | 44.76 | 49.38 | 32.22 | |
Average Inventory |
150.25 | 149.28 | 173.40 | 158.33 | |
Average Assets |
527.11 | 523.94 | 587.49 | 571.12 | |
Average Common Equity |
403.18 | 403.93 | 422.34 | 419.49 |
Columns are period end dates